Invention Grant
US08642045B2 Recombinant virus vector originating in HHV-6 or HHV-7, method of producing the same, method of transforming host cell using the same, host cell transformed thereby and gene therapy method using the same 有权
源自HHV-6或HHV-7的重组病毒载体,其制备方法,使用其转化宿主细胞的方法,由此转化的宿主细胞和使用其的基因治疗方法

  • Patent Title: Recombinant virus vector originating in HHV-6 or HHV-7, method of producing the same, method of transforming host cell using the same, host cell transformed thereby and gene therapy method using the same
  • Patent Title (中): 源自HHV-6或HHV-7的重组病毒载体,其制备方法,使用其转化宿主细胞的方法,由此转化的宿主细胞和使用其的基因治疗方法
  • Application No.: US10570589
    Application Date: 2004-08-30
  • Publication No.: US08642045B2
    Publication Date: 2014-02-04
  • Inventor: Kazuhiro Konda
  • Applicant: Kazuhiro Konda
  • Applicant Address: JP Osaka
  • Assignee: Virus Ikagaku Kenkyusho Inc.
  • Current Assignee: Virus Ikagaku Kenkyusho Inc.
  • Current Assignee Address: JP Osaka
  • Agency: Edwards Wildman Palmer LLP
  • Agent David G. Conlin
  • Priority: JP2003-307335 20030829
  • International Application: PCT/JP2004/012487 WO 20040830
  • International Announcement: WO2005/021746 WO 20050310
  • Main IPC: C12N15/00
  • IPC: C12N15/00 C12N15/09 C12N15/11 C12N15/33 C12N15/36 C12N15/63
Recombinant virus vector originating in HHV-6 or HHV-7, method of producing the same, method of transforming host cell using the same, host cell transformed thereby and gene therapy method using the same
Abstract:
It is intended to provide a virus vector by which an exogenous nucleotide sequence can be inserted and easily transferred into a mammalian host cell and a gene encoded by the exogenous nucleotide sequence can be expressed in the host cell, and which has a low risk of pathogenicity and is appropriately usable in gene therapy of mammals. Namely, a recombinant vector originating in HHV-6 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U5, U6, U7, U8, U24, and U25 regions of HHV-6; or a recombinant vector originating in HHV-7 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U7, U8, U24, U24a, and U25 regions of HHV-7.
Information query
Patent Agency Ranking
0/0